Need to keep on prime of the science and politics driving biotech immediately? Enroll to get our biotech e-newsletter in your inbox.
The inventor of a few of AI’s technical underpinnings is shifting focus to an RNA startup. Additionally, Rick Pazdur has some concepts on easy methods to decide whether or not Revolution Medicines’ pancreatic most cancers drug can work in a first-line setting. And an oncologist explains why she believes the failed Grail trial issues.
The AI architect taking goal at RNAi
Jakob Uszkoreit helped create the transformer structure — the “T” in ChatGPT — that sparked the generative AI growth. Now he’s making an attempt to do one thing simply as bold in drug growth, STAT’s Brittany Trang writes. His startup, Inceptive Nucleics, is constructing organic basis fashions that may be utilized throughout a variety of sequence-based medicines, from RNA interference therapies to mRNA and antisense medicine.
This text is unique to STAT+ subscribers
Unlock this text — plus in-depth evaluation, newsletters, premium occasions, and information alerts.
Have already got an account? Log in
View All Plans
